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Background
Although the durability of antiretroviral (ARV) efficacy
has improved, mainly due to better tolerability, ease of
administration (adherence) and potency, some patients
still encounter virological and immunological treatment
failure. These patients have been on multiple regimens
containing nucleoside reverse transcriptase inhibitors
(NRTIs), non-nucleoside reverse transcriptase inhibitor
(NNRTI) and Protease Inhibitor (PI) and have become
resistant to one or more of these classes. Hence, the
need for salvage therapies using newly approved antire-
trovirals that are NRTI, NNRTI and PI sparing is a clin-
ical reality. Raltegravir, maraviroc and etravirine are 3
new agents with distinguished characteristics which are
now available however guidelines for their use continue
to evolve and none exist yet on using them all in combi-
nation. In this study we reviewed patients who were four
ARV class experienced and on salvage regimens consist-
ing of a combination of raltegravir, etravirine and
maraviroc.
Methods
We retrospectively evaluated pts who had documented
failure to 3 or 4 different classes of ARVs and were trea-
ted with combination of RAL, MVC and ETV. Salvage
therapy was prescribed according to: viral tropism,
screening genotype and previous resistance tests. Our
inclusion criteria was 1) 3 or 4 ARV class experienced,
2) CXCR5 on troFile assay 3) on a regimen containing
maraviroc, raltegravir and etravirine together. Data was
reviewed and analyzed at baseline and at 24 weeks.
Results
9 out of 5500 charts fit this inclusion criterion. The
mean age was 50 yeras-old (34-62) with majority being
male (7/9, 78%). All pts were integrase-inhibitor (RAL)
naive and harboring CCR5 tropic virus. The median
ETV mutation score was 2.5 (range 0-2.5). The median
CD4-cell count and HIV-RNA levels were respectively
200 cells/mm3 (range: 19-734) and 4.4 log10 copies/mL
(2.3-5.6) at baseline. At week-24 the CD4-cell count was
389 cells/mm3 . The percentage of pts achieving HIV-
RNA levels <400 log10 copies/mL and <50 log10 copies/
mL at week 24 were respectively 78% (7/9) and 67% (6/
9). In the 2 patients that did not achieve <400 log10
copies/mL HIV-RNA levels poor ARV adherence was
documented. All pts tolerated this regimen well with no
discontinuation due to adverse events up to 24 weeks.
Discussion
The combination of RAL, MVC and ETV is safe and
highly efficacious in the management of HIV-treatment
experienced patients with excellent CD4-cell count
recovery and complete viral load suppression with good
ARV adherence.
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